Press release
Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Transforming Growth Factor Beta Inhibitors Pipeline Report to explore emerging therapies, key Transforming Growth Factor Beta Inhibitors Companies, and future Transforming Growth Factor Beta Inhibitors treatment landscapes @ Transforming Growth Factor Beta Inhibitors Pipeline Outlook Report [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Transforming Growth Factor Beta Inhibitors Pipeline Report
* DelveInsight's Transforming Growth Factor Beta Inhibitors pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Transforming Growth Factor Beta Inhibitors treatment.
* The leading Transforming Growth Factor Beta Inhibitors Companies such as Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
* Promising Transforming Growth Factor Beta Inhibitors Therapies such as Trabedersen, KER-050, STP705 , and others.
Discover how the Transforming Growth Factor Beta Inhibitors treatment paradigm is evolving. Access DelveInsight's in-depth Transforming Growth Factor Beta Inhibitors Pipeline Analysis for a closer look at promising breakthroughs @ Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Transforming Growth Factor Beta Inhibitors Emerging Drugs Profile
* Trabedersen: Oncotelic
Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-2 messenger RNA. Ready for registration trials--Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.
* KER-050: Keros Therapeutics
KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF- receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF- family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.
* STP705: Sirnaomics
STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.
Get a detailed analysis of the latest innovations in the Transforming Growth Factor Beta Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ Transforming Growth Factor Beta Inhibitors Unmet Needs [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Transforming Growth Factor Beta Inhibitors Companies
Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
Transforming Growth Factor Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
Transforming Growth Factor Beta Inhibitors Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming Transforming Growth Factor Beta Inhibitors Therapies and key Transforming Growth Factor Beta Inhibitors Developments @ Transforming Growth Factor Beta Inhibitors Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Transforming Growth Factor Beta Inhibitors Pipeline Report
* Coverage- Global
* Transforming Growth Factor Beta Inhibitors Companies- Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
* Transforming Growth Factor Beta Inhibitors Therapies- Trabedersen, KER-050, STP705 , and others.
* Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Transforming Growth Factor Beta Inhibitors drug development? Find out in DelveInsight's exclusive Transforming Growth Factor Beta Inhibitors Pipeline Report-access it now! @ Transforming Growth Factor Beta Inhibitors Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Transforming growth factor beta inhibitors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Transforming growth factor beta inhibitors - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Transforming growth factor beta inhibitors Collaboration Deals
* Late Stage Products (Phase III)
* Trabedersen: Oncotelic
* Mid Stage Products (Phase II)
* KER-050: Keros Therapeutics
* STP705: Sirnaomics
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Transforming growth factor beta inhibitors Key Companies
* Transforming growth factor beta inhibitors Key Products
* Transforming growth factor beta inhibitors- Unmet Needs
* Transforming growth factor beta inhibitors- Market Drivers and Barriers
* Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
* Transforming growth factor beta inhibitors Analyst Views
* Transforming growth factor beta inhibitors Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=transforming-growth-factor-beta-inhibitors-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/venous-thromboembolism-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3860691 • Views: …
More Releases from ABNewswire
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Transforming
Transforming Lives , Together
Unessa Foundation is a purpose-driven organization committed to transforming lives, together. Built on the belief that unity and compassion are the cornerstones of meaningful change, Unessa empowers individuals and communities through inclusive programs, collaborative efforts, and a people-first approach.
Rooted in dignity, empathy, and impact, our mission is to uplift underrepresented voices, close opportunity gaps, and strengthen human connections that create lasting social change. At Unessa, we see every person as…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
Transforming Higher Education Admissions
Radius X, a user-friendly platform for admission automation and data analysis, is now available for higher education providers. Designed to simplify the admissions process, Radius X enhances the student experience through self-service options and automation.
Admissions teams today face growing challenges as they handle more applications and higher expectations from students. Many are overwhelmed by paperwork and manual tasks that take away valuable time. Radius X addresses these struggles by…
Curiotory: Transforming Language Learning
India's ultimate language learning app
Curiotory is a language learning platform dedicated to creating an enjoyable and effective learning experience. With a focus on online language learning, Curiotory empowers learners to achieve fluency and cultural understanding.
Curiotory, a trailblazer in the language learning industry, is proud to announce its continued commitment to providing a unique, immersive, and personalized approach to language education. With a mission to bridge cultural gaps and make…
Transforming Smiles, Transforming Lives: Introducing Dr. Robert Rifkin, the Maes …
Image: https://www.getnews.info/uploads/3cc5ecdc456666ed434d2b2f5410c024.png
Dr. Robert Rifkin, the visionary force behind some of the most iconic smiles worldwide, continues to redefine the standards of cosmetic dentistry. With over four decades of unparalleled expertise, Dr. Rifkin has earned his place as the godfather of cosmetic dentistry, revolutionizing the field with his innovative treatments and unparalleled artistry.
A Legacy of Innovation
For over 40 years, Dr. Robert Rifkin has been at the forefront of cosmetic dentistry in…
